Authors:
Melania Gaggini
1
;
Renata De Maria
1
;
Chiara Saponaro
1
;
Emma Buzzigoli
1
;
Demetrio Ciociaro
1
;
Sylvie Normand
2
;
Giuseppe Coppini
1
;
Martine Laville
2
;
Paolo Marraccini
1
and
Amalia Gastaldelli
1
Affiliations:
1
Institute of Clinical Physiology CNR, Italy
;
2
Centre Européen Nutrition Santé CENS, France
Keyword(s):
Cardiometabolic Risk, Abdominal Adiposity, Metabolic Syndrome.
Abstract:
Cardiovascular and metabolic diseases are the major causes of morbidity and mortality in the Western Countries. Metabolic syndrome (defined as 3 out of 5 factors among increased waist circumference, hypertension, high blood glucose, high triglyceride and low high density lipoprotein (HDL) cholesterol concentrations) is associated with increased cardiometabolic risk. Other indexes have been proposed and validated, based on the measurement of plasma concentration of lipids, glucose and liver enzymes. In the SEMEOTICONS project we plan to measure parameters related to increased cardiometabolic risk, e.g. skin accumulation of cholesterol and advanced glycated end products, liver enzyme alteration by changing in skin and eye color and obesity. The results will allow to evaluate cardiometabolic risk using non invasive clinical parameters. The new score obtained will be compared with previously validated indexes. In this paper we have evaluated the most common cardiometabolic risk scores i.
e., VAI (Visceral Adiposity Index), HTG- Waist (Hypertriglyceridemic Waist), FLI (Fatty Liver Index) and LAP (Lipid Accumulation Product), that we will use during the project.
(More)